188
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma

, , , , , & show all
Pages 2268-2269 | Received 29 Nov 2016, Accepted 25 Jan 2017, Published online: 20 Feb 2017
Supplemental material

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Download Zip (7.1 MB)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.